Clinical trial
A Phase II Study of Darbepoetin Alpha in Myelodysplastic Syndromes (MSD)
NCT00443339 is registered in ClinicalTrials.gov with Groupe Francophone des Myelodysplasies as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Study of Darbepoetin Alpha in Myelodysplastic Syndromes (MSD)
- Lead sponsor
- Groupe Francophone des Myelodysplasies
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- December 31, 2006
- Completion date
- July 31, 2008
- Enrollment
- 99 (estimated)
- Sites
- 29
Conditions
As the registry lists them; a condition with its own page is linked.